The University of Strathclyde’s Centre for Innovative Manufacturing in Continuous Manufacturing and Advanced Crystallisation (CMAC) and Future Manufacturing Research Hub is pioneering new ways to:
- develop and make medicines
- drive innovation in manufacturing.
It is backed by over £16 million of EPSRC investment.
The centre has reported a number of early successes in particular around the application of digital twin modelling.
A major hub
The centre is now operating as a major hub for British and European medicine manufacturing and has attracted £120 million in investment to Glasgow and the surrounding region.
- brought £150 million of investment into the area
- created jobs for 130 people, including academics, post-docs, PhD students and technicians.
Professor Alastair Florence, CMAC’s Director said:
In a world changed forever by COVID-19, everyone stands to win from flexible, secure, sustainable, cost-effective medicines manufacturing.
This region aims to help the UK become the place to make novel medicines in novel ways.
Without EPSRC’s support and sponsorship, it simply couldn’t have happened.
CMAC is closely aligned to the pharma industry, with companies such as GlaxoSmithKline, Novartis and AstraZeneca signing up as founding partners.
Jon-Paul Sherlock, AstraZeneca’s Global Technology Strategy Director said:
We recognised CMAC’s intention to be ‘a place of useful learning’ and respond to industry needs.
Appointment of an industry lead from within industry was another strong message of intent.
Our products and processes are already benefitting from CMAC.
CMAC has also received funding from Research England’s UK Research Partnership Investment Fund.
Read more about Continuous Manufacturing and Advanced Crystallisation (CMAC).
Video credit: UKRI
An autogenerated transcript of the video is available on YouTube.
Last updated: 7 June 2021